Literature DB >> 8555490

Persistent activation of the tumor necrosis factor system in a subgroup of patients with common variable immunodeficiency--possible immunologic and clinical consequences.

P Aukrust1, E Lien, A K Kristoffersen, F Müller, C J Haug, T Espevik, S S Frøland.   

Abstract

In patients with common variable immunodeficiency (CVI), we have previously defined a subgroup of patients (CVIHyper) characterized by decreased numbers of CD4+ lymphocytes in peripheral blood, splenomegaly, and persistent immune activation in vivo, particularly of monocytes/macrophages. To further characterize this hyperactivity, parameters of activation of the tumor necrosis factor (TNF) system (TNF alpha and soluble TNF receptors [sTNFRs]) were measured in 24 patients with CVI and 20 healthy controls. Patients with CVI had significantly higher serum levels of TNF alpha and both types of sTNFRs, with the highest levels in the CVIHyper subgroup. In vitro, peripheral blood mononuclear cells (PBMC) and purified monocytes from CVIHyper patients spontaneously released significantly higher levels, and, after lipopolysaccharide (LPS) stimulation, significantly lower levels of TNF alpha and soluble p75-TNFR than cells from both other CVI patients and healthy controls. CVIHyper patients also had significantly higher TNF alpha:sTNFRs ratios in both serum and in unstimulated PMBC supernatants. The present study demonstrates persistent in vivo activation of the TNF system in CVI, particularly in the CVIHyper subgroup. This activation may contribute to the pathogenesis of both clinical and immunologic manifestations in CVI.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8555490

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

Review 1.  Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID).

Authors:  L Hammarström; I Vorechovsky; D Webster
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

Review 2.  How I treat common variable immune deficiency.

Authors:  Charlotte Cunningham-Rundles
Journal:  Blood       Date:  2010-03-23       Impact factor: 22.113

3.  Increased expression of chemokines in patients with Wegener's granulomatosis - modulating effects of methylprednisolone in vitro.

Authors:  E A Torheim; A Yndestad; V Bjerkeli; B Halvorsen; P Aukrust; S S Frøland
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

Review 4.  Common variable immune deficiency: reviews, continued puzzles, and a new registry.

Authors:  Charlotte Cunningham-Rundles; Adina Kay Knight
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

5.  Common variable immunodeficiency-associated myelitis: report of treatment with infliximab.

Authors:  N Kumar; J B Hagan; R S Abraham; A J Aksamit
Journal:  J Neurol       Date:  2008-07-21       Impact factor: 4.849

Review 6.  Pathogenesis and treatment of gastrointestinal disease in antibody deficiency syndromes.

Authors:  Shradha Agarwal; Lloyd Mayer
Journal:  J Allergy Clin Immunol       Date:  2009-08-08       Impact factor: 10.793

7.  Infliximab for treatment of granulomatous disease in patients with common variable immunodeficiency.

Authors:  Timothy J Franxman; Laura E Howe; James R Baker
Journal:  J Clin Immunol       Date:  2014-07-27       Impact factor: 8.317

8.  Proinflammatory cytokine gene single nucleotide polymorphisms in common variable immunodeficiency.

Authors:  N Rezaei; A A Amirzargar; Y Shakiba; M Mahmoudi; B Moradi; A Aghamohammadi
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

9.  Adhesion molecules in common variable immunodeficiency (CVID)--a decrease in L-selectin-positive T lymphocytes.

Authors:  I Nordøy; F Müller; P Aukrust; S S Frøland
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

Review 10.  Development of granulomatous common variable immunodeficiency subsequent to infection with Toxoplasma gondii.

Authors:  S Mrusek; A Marx; J Kummerle-Deschner; N Tzaribachev; A Enders; U-N Riede; K Warnatz; G E Dannecker; S Ehl
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.